What is elranatamab? A Bispecific Antibody for Multiple Myeloma
•
3 min read
The FDA granted accelerated approval to elranatamab (Elrexfio) in August 2023, making it a new, “off-the-shelf” treatment option for certain adults with heavily pretreated relapsed or refractory multiple myeloma. This innovative immunotherapy, part of a new class of bispecific T-cell engagers, provides a vital alternative for patients whose cancer has progressed after multiple prior therapies.
